Kartik Gupta, Sravan Dubasi and Arvind Kumar, Naveet Wig. Neuroleptic Malignant Syndrome and Elevated CSF Protein with Quetiapine: Case Report and Review of Literature.
. 2017; 5(4):79-82. doi: 10.12691/AJMCR-5-4-1
Neuroleptic malignant syndrome (NMS), atypical antipsychotics, Quetiapine
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Delay J et al. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 1960 [cited 8 April 2017]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/13815606. |
|
[2] | Gurrera R, Simpson J, Tsuang M. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. 2006. |
|
[3] | Wilmington, DE. Product Information. AstraZenca; 2008. |
|
[4] | Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. Journal of Psychiatric Research. 1995; 29(3): 233-244. |
|
[5] | Arnaout M, Antun F, Ashkar K. Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia. Human Psychopharmacology: Clinical and Experimental. 2001; 16(3): 279-281. |
|
[6] | Sharma B, Sannegowda R, Gandhi P, Dubey P, Panagariya A. Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: a rare occurrence. Case Reports. 2013; 2013 (jun11 1): bcr2013008908-bcr2013008908. |
|
[7] | Supariwala A, Kant G, Jean R. Neuroleptic malignant syndrome with metoclopramide overdose coexisting with Clostridium difficile diarrhea. Intensive Care Medicine. 2011; 37(10):1706-1708. |
|
[8] | Trollor J, Chen X, Sachdev P. Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs. CNS Drugs. 2009; 23(6):477-492. |
|
[9] | Patil V, Gupta R, Verma R, Singh Balhara Y. Neuroleptic Malignant Syndrome Associated with Lithium Toxicity. Oman Medical Journal. 2016;31(4):309-311. |
|
[10] | JL L. Neuroleptic malignant syndrome. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2017 [cited 8 April 2017]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2863986 |
|
[11] | Mathews T, Aderibigbe Y. Proposed research diagnostic criteria for neuroleptic malignant syndrome. The International Journal of Neuropsychopharmacology. 1999;2(2):129-144. |
|
[12] | Odagaki Y. Atypical Neuroleptic Malignant Syndrome or Serotonin Toxicity Associated with Atypical Antipsychotics?. Current Drug Safety. 2009;4(1):84-93. |
|
[13] | Farver D. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opinion on Drug Safety. 2003; 2(1): 21-35. |
|
[14] | Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D: American Psychiatric Association; 2013. |
|
[15] | RJ G. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2017 [cited 8 April 2017]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28144982 |
|
[16] | Strawn J, Keck P, Caroff S. Neuroleptic Malignant Syndrome. American Journal of Psychiatry. 2007;164(6):870-876. |
|
[17] | Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs. The Journal of Clinical Psychiatry. 2004;65(4):464-470. |
|
[18] | Ishioka M, Yasui-Furukori N, Hashimoto K, Sugawara N. Neuroleptic Malignant Syndrome Induced by Lamotrigine. Clinical Neuropharmacology. 2013; 36(4): 131-132. |
|
[19] | Farver D. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opinion on Drug Safety. 2003;2(1):21-35. |
|
[20] | Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P et al. Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia. CNS Drugs. 2006; 20(5): 389-409. |
|